Covaxin is the first indigenous vaccine candidate by India to fight against the novel coronavirus, developed by Bharat Biotech India (BBIL), Hyderabad-based biotechnology firm working closely with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).
Covaxin falls under the category of inactivated vaccines, which means the virus pathogen is ‘deactivated’ and has no possibility of infecting a person or multiplying in number, as it is already dead.
According to the firm, “The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine was developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad, India.”
Therefore, the vaccine just serves the immune system as a dead virus and mounts an antibody response towards the virus.